BACKGROUND: In contrast to the prominent function of the blood vasculature in promoting tissue inflammation, the role of lymphatic vessels in inflammation has been scarcely studied in vivo. To investigate whether modulating lymphatic vessel function might affect the course of chronic inflammation, the major lymphangiogenic receptor, vascular growth factor receptor 3 (VEGFR-3, FLT4), was blocked in an established model of inflammatory bowel disease. METHODS: Interleukin 10 (IL10)-deficient mice that spontaneously develop inflammatory bowel disease were treated with a blocking antibody to VEGFR-3 for 18 days, and the inflammatory changes in colon tissue and the blood and lymphatic vascularization were quantitatively analyzed. RESULTS: We found a significant increase in the severity of colon inflammation in anti-VEGFR-3-treated mice. This was accompanied by an increased number of enlarged and tortuous lymphatic vessels and edema in colon submucosa, indicating impaired lymphatic function. In contrast, no major effects of the treatment on the blood vasculature were observed. CONCLUSIONS: These results indicate that therapies aimed at promoting lymphatic function, e.g., with prolymphangiogenic factors, such as VEGF-C, might provide a novel strategy for the treatment of inflammatory conditions, such as inflammatory bowel disease.
BACKGROUND: In contrast to the prominent function of the blood vasculature in promoting tissue inflammation, the role of lymphatic vessels in inflammation has been scarcely studied in vivo. To investigate whether modulating lymphatic vessel function might affect the course of chronic inflammation, the major lymphangiogenic receptor, vascular growth factor receptor 3 (VEGFR-3, FLT4), was blocked in an established model of inflammatory bowel disease. METHODS:Interleukin 10 (IL10)-deficient mice that spontaneously develop inflammatory bowel disease were treated with a blocking antibody to VEGFR-3 for 18 days, and the inflammatory changes in colon tissue and the blood and lymphatic vascularization were quantitatively analyzed. RESULTS: We found a significant increase in the severity of colon inflammation in anti-VEGFR-3-treated mice. This was accompanied by an increased number of enlarged and tortuous lymphatic vessels and edema in colon submucosa, indicating impaired lymphatic function. In contrast, no major effects of the treatment on the blood vasculature were observed. CONCLUSIONS: These results indicate that therapies aimed at promoting lymphatic function, e.g., with prolymphangiogenic factors, such as VEGF-C, might provide a novel strategy for the treatment of inflammatory conditions, such as inflammatory bowel disease.
Authors: I J Bristol; M A Farmer; Y Cong; X X Zheng; T B Strom; C O Elson; J P Sundberg; E H Leiter Journal: Inflamm Bowel Dis Date: 2000-11 Impact factor: 5.325
Authors: Bronislaw Pytowski; Jeremy Goldman; Kris Persaud; Yan Wu; Larry Witte; Daniel J Hicklin; Mihaela Skobe; Kendrick C Boardman; Melody A Swartz Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506
Authors: T Mäkinen; T Veikkola; S Mustjoki; T Karpanen; B Catimel; E C Nice; L Wise; A Mercer; H Kowalski; D Kerjaschki; S A Stacker; M G Achen; K Alitalo Journal: EMBO J Date: 2001-09-03 Impact factor: 11.598
Authors: Ruolin Guo; Quan Zhou; Steven T Proulx; Ronald Wood; Rui-Cheng Ji; Christopher T Ritchlin; Bronislaw Pytowski; Zhenping Zhu; Yong-Jun Wang; Edward M Schwarz; Lianping Xing Journal: Arthritis Rheum Date: 2009-09
Authors: Maike F de Buhr; Hans-J Hedrich; Astrid M Westendorf; Florian Obermeier; Claudia Hofmann; Nils-H Zschemisch; Jan Buer; Dirk Bumann; Sanna M Goyert; Andre Bleich Journal: Inflamm Bowel Dis Date: 2009-07-27 Impact factor: 5.325
Authors: Tuomas Tammela; Georgia Zarkada; Elisabet Wallgard; Aino Murtomäki; Steven Suchting; Maria Wirzenius; Marika Waltari; Mats Hellström; Tibor Schomber; Reetta Peltonen; Catarina Freitas; Antonio Duarte; Helena Isoniemi; Pirjo Laakkonen; Gerhard Christofori; Seppo Ylä-Herttuala; Masabumi Shibuya; Bronislaw Pytowski; Anne Eichmann; Christer Betsholtz; Kari Alitalo Journal: Nature Date: 2008-06-25 Impact factor: 49.962
Authors: Simon Schwager; Silvana Renner; Teresa Hemmerle; Sinem Karaman; Steven T Proulx; Roman Fetz; Alexandra Michaela Golding-Ochsenbein; Philipp Probst; Cornelia Halin; Dario Neri; Michael Detmar Journal: JCI Insight Date: 2018-12-06
Authors: Michael Simons; Kari Alitalo; Brian H Annex; Hellmut G Augustin; Craig Beam; Bradford C Berk; Tatiana Byzova; Peter Carmeliet; William Chilian; John P Cooke; George E Davis; Anne Eichmann; M Luisa Iruela-Arispe; Eli Keshet; Albert J Sinusas; Christiana Ruhrberg; Y Joseph Woo; Stefanie Dimmeler Journal: Circ Res Date: 2015-04-30 Impact factor: 17.367
Authors: Anna K Polomska; Steven T Proulx; Davide Brambilla; Daniel Fehr; Mathias Bonmarin; Simon Brändli; Mirko Meboldt; Christian Steuer; Tsvetina Vasileva; Nils Reinke; Jean-Christophe Leroux; Michael Detmar Journal: JCI Insight Date: 2019-02-21
Authors: Audrey Seamons; Piper M Treuting; Stacey Meeker; Charlie Hsu; Jisun Paik; Thea Brabb; Sabine S Escobar; Jonathan S Alexander; Aaron C Ericsson; Jason G Smith; Lillian Maggio-Price Journal: Am J Pathol Date: 2018-05-18 Impact factor: 4.307
Authors: Felix Becker; Emily Romero; Jason Goetzmann; Dana L Hasselschwert; Beth Dray; John Vanchiere; Jane Fontenot; J Winny Yun; Paul C Norris; Luke White; Melany Musso; Charles N Serhan; J Steven Alexander; Felicity N E Gavins Journal: Am J Pathol Date: 2019-10 Impact factor: 4.307